On Sept. 9, 2020, Valneva announced the signing of a new contract, lasting up to three years, with the U.S. government Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIAROﾮ.

The new contract spans a total of three years (one base year, plus two option years) with a base-year value of $61 million.